<DOC>
	<DOCNO>NCT01330693</DOCNO>
	<brief_summary>The purpose study find child attention-deficit , hyperactivity disorder ( ADHD ) difference brain cell `` fire '' react . The investigator also want find brain cell `` firing '' tell u severe symptom child ADHD . Finally , investigator want see give ADHD medication call atomoxetine make ADHD symptom child well improvement show change brain `` firing '' .</brief_summary>
	<brief_title>Cortical Excitability : Phenotype Biomarker Attention-deficit , Hyperactivity Disorder ( ADHD ) Therapy</brief_title>
	<detailed_description>This study evaluate Short Interval Intracortical Inhibition ( SICI ) measure pTMS marker hyperactive-impulsive dimension 120 ADHD 7-12 year , medication-free child . This study characterize effect single dose atomoxetine compare placebo cognitive correlate SICI change . Participants randomize 2:1 either atomoxetine placebo . The study also characterize effect four week atomoxetine treatment cortical inhibition correlate SICI change clinical outcome .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>1 . Signed informed consent assent 2 . Meets DSMIV criterion ADHD , combine inattentive subtype , base KSADS interview 3 . Scores least 1.5 SD high age gender mean ADHD RS , key ADHD subtype ( i.e. , combine score combine subtype , inattentive subscale inattentive subtype , etc . ) 4 . Age : 7 12 year study entry 5 . Findings physical exam , laboratory study ECG judge normal age gender , determine study physician study entry 6 . There coexist medical condition TMS ATX contraindicate ( example pheochromocytoma ) . 7 . Pulse blood pressure within 95 % age gender mean 8 . Full scale IQ &gt; 75 ( i.e. , exclude mental retardation lower level borderline range ) 9 . Able complete study instrument swallow capsule 10 . Willing commit entire visit schedule study 11 . No previous treatment Atomoxetine 12 . Must either naive ADHD study medication well current ADHD medication . 1 . Has one follow exclusionary diagnosis : autism/ pervasive developmental disorder , mental retardation , schizophrenia , psychotic disorder , bipolar disorder , severe depressive conduct disorder 2 . Has comorbid disorder otherwise allowable , require treatment offer study , primary focus treatment , opinion PI 3 . Has medical neurologic disorder would preclude take ATX , would potentially confound assessment ADHD and/or TMS outcomes , opinion PI ( example pheochromocytoma , specific purpose study uncontrolled seizure disorder organic brain syndrome ) . 4 . Taking systemic medication might interfere metabolism efficacy assessment ATX study 5 . History allergic reaction multiple medication 6 . History alcohol drug abuse past 3 month Has medication treatment study past 30 day 7 . Females childbearing age sexually active , use acceptable birth control ( double barrier method ) , abstinent . Abstinence define sexual activity least 3 month start study intention abstain sexual activity study period ) . Double barrier method allow include : condom diaphragms combine spermicide use , intrauterine device ( IUD ) , oral , transdermal , injectable implantable hormonal medication ( OrthoEvra , Norplant , DepoProvera , similar prescription product ) least one month enter study continue use throughout study . Birth control pills alone acceptable form birth control study . 8 . Has prior neurological condition might increase risk adverse event TMS . For purpose study exclude child current prior history epilepsy .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Atomoxetine</keyword>
	<keyword>Biomarker</keyword>
</DOC>